Analyst Kevin Kedra works at GABELLI and is focused on the Healthcare sector with 19 price targets and ratings documented since 2016 spanning on 3 stocks. Analyst's average stock valuation to be materialised ratio is 75% with an average time for price targets to be met of 155.5 days.
Most recent stock forecast was given on LXRX, Lexicon Pharmaceuticals, Inc at 15-Jan-2021.
Kevin Kedra best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS, INC).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS, INC) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.
Average potential price target upside
Currently, out of the existing stock ratings of Kevin Kedra - 1115 which are a Buy (47.27%), 929 which are a Hold (39.38%), 315 which are a Sell (13.35%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
18
8 months 28 days ago
5/14 (35.71%)
$7.93 (191.40%)
39
Hold
6
$3.68 (158.62%)
3
2 years 18 days ago
3/7 (42.86%)
$5.92 (73.77%)
59
Hold
2
$-0.32 (-13.79%)
34
2 years 2 months ago
2/11 (18.18%)
$15.78 (153.81%)
409
Hold
7
$4.78 (215.32%)
2 years 2 months ago
3/3 (100%)
$1.33 (13.05%)
55
Hold
2 years 2 months 14 days ago
1/1 (100%)
$0.8 (36.36%)
7
